

Vassilis Golfopoulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10740115/publications.pdf>

Version: 2024-02-01

19
papers

4,137
citations

567281

15
h-index

794594

19
g-index

20
all docs

20
docs citations

20
times ranked

6349
citing authors

#	ARTICLE	IF	CITATIONS
1	Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , 2022, 24, 755-767.	1.2	25
2	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. <i>Acta Neuropathologica</i> , 2021, 141, 945-957.	7.7	32
3	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. <i>Neuro-Oncology</i> , 2021, 23, 1547-1559.	1.2	34
4	Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. <i>European Journal of Cancer</i> , 2021, 147, 1-12.	2.8	10
5	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC) Tj ETQq1 1 0.784314 rgBT /O Oncology, The, 2021, 22, 813-823.	10.7	132
6	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 684-693.	1.2	126
7	Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. <i>Neuro-Oncology</i> , 2019, 21, 1587-1594.	1.2	56
8	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. <i>Neurology</i> , 2019, 92, e2754-e2763.	1.1	9
9	Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. <i>Lancet Oncology, The</i> , 2018, 19, 1170-1179.	10.7	80
10	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. <i>Neuro-Oncology</i> , 2017, 19, 1119-1126.	1.2	107
11	Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. <i>New England Journal of Medicine</i> , 2017, 376, 1027-1037.	27.0	810
12	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet, The</i> , 2017, 390, 1645-1653.	13.7	307
13	Lomustine and Bevacizumab in Progressive Glioblastoma. <i>New England Journal of Medicine</i> , 2017, 377, 1954-1963.	27.0	670
14	Precision Medicine: From "Omics" to Economics towards Data-Driven Healthcare - Time for European Transformation. <i>Biomedicine Hub</i> , 2017, 2, 1-10.	1.2	7
15	Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion. <i>Journal of Clinical Oncology</i> , 2017, 35, 2009-2009.	1.6	8
16	70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 717-729.	27.0	1,427
17	Evaluating novel agent effects in multiple treatments meta-regression. <i>Statistics in Medicine</i> , 2010, 29, 2369-2383.	1.6	84
18	Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. <i>Lancet Oncology, The</i> , 2007, 8, 898-911.	10.7	149

#	ARTICLE	IF	CITATIONS
19	Treatment of colorectal cancer in the elderly: A review of the literature. <i>Cancer Treatment Reviews</i> , 2006, 32, 1-8.	7.7	64